Clinic of Surgery, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.
Anticancer Res. 2012 Sep;32(9):3769-74.
Photodynamic therapy (PDT) is a clinically-accepted approach for the therapy of many types of cancer. This study focused on the treatment of mammarian carcinoma by topical administration of hydroxyl-aluminium phthalocyanine (AlOH-PC), compared to a clinically-approved photosensitizer (Metvix, Galderma & PhotoCure ASA, Inc., Oslo, Norway).
MDA-MB 231 cells were subcutaneously injected into the right flank of athymic nude mice. Mice with grown tumours were used for in vivo efficacy studies. Different doses of liposomal AlOH-PC were applied to determine the most effective dose. In later studies, Metvix or our liposomal-AlOH-PC gel formula were used. Topical application of photosensitizers was followed by the PDT irradiation at 600-700 nm (635 nm peak). Tumour growth was measured three times weekly.
Therapeutic studies revealed that AlOH-PC treatment led to complete tumour remission in 90% (9/10) of experimental animals, whereas usage of the commercially available Metvix only postponed the tumour growth. Moreover, usage of liposomal AlOH-PC shortened the time allowed between the application of the photosensitizer and light exposure: for Metvix, hours are usually needed, while the tested liposomal AlOH-PC showed remarkable outcomes after only 10 min.
Liposomal AlOH-PC gel appears to be potentially suitable for PDT of mammarian carcinoma.
光动力疗法（PDT）是一种被临床认可的治疗多种癌症的方法。本研究专注于通过局部给予羟基铝酞菁（AlOH-PC）治疗乳腺癌，与一种临床批准的光敏剂（Metvix，Galderma 和 PhotoCure ASA，奥斯陆，挪威）进行比较。
MDA-MB 231 细胞被皮下注射到无胸腺裸鼠的右侧侧腹。生长肿瘤的小鼠用于体内疗效研究。给予不同剂量的脂质体 AlOH-PC，以确定最有效的剂量。在后来的研究中，使用了 Metvix 或我们的脂质体 AlOH-PC 凝胶配方。在 600-700nm（635nm 峰）进行 PDT 照射之前，局部应用光敏剂。每周测量三次肿瘤生长情况。
治疗研究表明，AlOH-PC 治疗导致 90%（9/10）的实验动物完全肿瘤消退，而商业上可获得的 Metvix 仅推迟了肿瘤生长。此外，使用脂质体 AlOH-PC 缩短了光敏剂应用和光照之间的时间间隔：对于 Metvix，通常需要几个小时，而经过测试的脂质体 AlOH-PC 在仅 10 分钟后就显示出显著的效果。
脂质体 AlOH-PC 凝胶似乎适合用于乳腺癌的 PDT。
